JP Morgan Maintains Overweight on Abbott Laboratories, Raises Price Target to $120

Benzinga Newsdesk www.benzinga.com Positive 77.4%

Neg 0% Neu 0% Pos 77.4%

JP Morgan analyst Robbie Marcus maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $110 to $120.